Drug profile · INN
betamethasone acetate
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
betamethasone acetate (BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — betamethasone acetate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
betamethasone acetate (BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is betamethasone acetate?
betamethasone acetate (BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for betamethasone acetate?
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is a marketed brand name for betamethasone acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of betamethasone acetate?
betamethasone acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.